See more : Indaptus Therapeutics, Inc. (INDP) Income Statement Analysis – Financial Results
Complete financial analysis of HTG Molecular Diagnostics, Inc. (HTGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of HTG Molecular Diagnostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- MPS Limited (MPSLTD.NS) Income Statement Analysis – Financial Results
- PAVmed Inc (PAVMZ) Income Statement Analysis – Financial Results
- State Grid Information & Communication Co., Ltd. (600131.SS) Income Statement Analysis – Financial Results
- CF Industries Holdings, Inc. (0HQU.L) Income Statement Analysis – Financial Results
- GACM Technologies Limited (GATECH.BO) Income Statement Analysis – Financial Results
HTG Molecular Diagnostics, Inc. (HTGM)
About HTG Molecular Diagnostics, Inc.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.37M | 8.91M | 8.55M | 19.20M | 21.50M | 14.76M | 5.13M | 4.04M | 3.33M | 2.24M | 2.48M |
| Cost of Revenue | 4.57M | 4.09M | 3.99M | 8.91M | 5.09M | 4.97M | 4.14M | 3.34M | 3.20M | 2.25M | 1.82M |
| Gross Profit | 1.79M | 4.81M | 4.56M | 10.29M | 16.41M | 9.79M | 996.85K | 706.06K | 124.04K | -3.83K | 664.63K |
| Gross Profit Ratio | 28.18% | 54.02% | 53.31% | 53.60% | 76.33% | 66.31% | 19.42% | 17.47% | 3.73% | -0.17% | 26.79% |
| Research & Development | 6.78M | 6.09M | 6.08M | 10.57M | 12.60M | 10.00M | 7.90M | 4.60M | 3.08M | 4.20M | 3.92M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 19.97M | 17.51M | 17.43M | 14.99M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.84M | 16.55M | 18.06M | 18.68M | 19.97M | 17.51M | 17.43M | 14.99M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 8.33K | -1.03M | 22.27K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.90M | 7.71M | 7.29M |
| Operating Expenses | 22.62M | 22.64M | 24.14M | 29.25M | 32.57M | 27.51M | 25.33M | 19.60M | 12.97M | 11.91M | 11.21M |
| Cost & Expenses | 27.20M | 26.73M | 28.13M | 38.16M | 37.66M | 32.48M | 29.46M | 22.93M | 16.18M | 14.16M | 13.03M |
| Interest Income | 94.36K | 29.88K | 254.74K | 623.36K | 715.72K | 73.18K | 112.41K | 85.86K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 856.73K | 1.06M | 1.02M | 957.54K | 901.82K | 1.31M | 1.87M | 1.72M | 706.87K | 211.87K | 251.08K |
| Depreciation & Amortization | 689.83K | -1.74M | 1.62M | 2.36M | 1.47M | 1.24M | 1.47M | 662.56K | 496.60K | 315.09K | 222.63K |
| EBITDA | -20.14M | -19.56M | -17.96M | -16.60M | -14.08M | -16.41M | -22.69M | -19.01M | -12.75M | -11.24M | -12.30M |
| EBITDA Ratio | -316.35% | -219.60% | -210.11% | -86.45% | -65.48% | -111.17% | -442.03% | -470.25% | -383.15% | -501.21% | -495.81% |
| Operating Income | -20.83M | -17.82M | -19.59M | -18.96M | -16.16M | -17.72M | -24.33M | -18.89M | -12.85M | -11.92M | -10.55M |
| Operating Income Ratio | -327.19% | -200.11% | -229.10% | -98.73% | -75.15% | -120.08% | -474.04% | -467.39% | -385.97% | -531.21% | -425.21% |
| Total Other Income/Expenses | -754.04K | 701.13K | -1.27M | -334.18K | -291.16K | -1.23M | -1.70M | -2.50M | -1.11M | 146.05K | -2.23M |
| Income Before Tax | -21.58M | -17.12M | -20.86M | -19.29M | -16.45M | -18.96M | -26.03M | -21.39M | -13.96M | -11.77M | -12.77M |
| Income Before Tax Ratio | -339.03% | -192.24% | -243.96% | -100.47% | -76.50% | -128.44% | -507.13% | -529.19% | -419.30% | -524.70% | -514.91% |
| Income Tax Expense | 10.84K | 22.48K | 14.42K | 3.38K | 3.53K | 2.92K | 10.12K | 10.19K | -402.68K | 357.92K | -1.97M |
| Net Income | -21.59M | -17.15M | -20.87M | -19.30M | -16.45M | -18.96M | -26.04M | -21.40M | -13.96M | -11.77M | -12.77M |
| Net Income Ratio | -339.20% | -192.49% | -244.13% | -100.49% | -76.52% | -128.46% | -507.32% | -529.44% | -419.30% | -524.70% | -514.91% |
| EPS | -24.28 | -29.66 | -54.12 | -91.17 | -0.75 | -2.24 | -4.58 | -5.92 | -52.33 | -44.13 | -47.89 |
| EPS Diluted | -24.28 | -29.66 | -54.12 | -91.17 | -0.75 | -2.24 | -4.58 | -5.92 | -5.95 | -44.13 | -47.89 |
| Weighted Avg Shares Out | 889.28K | 578.01K | 385.66K | 211.66K | 22.02M | 8.48M | 5.69M | 3.61M | 266.72K | 266.72K | 266.72K |
| Weighted Avg Shares Out (Dil) | 889.28K | 578.01K | 385.66K | 211.66K | 22.02M | 8.48M | 5.69M | 3.61M | 2.35M | 266.72K | 266.72K |
Coronavirus Scare Supports These Biotech ETFs & Stocks
Analysts Are Bullish on Top Healthcare Stocks: CareDx (CDNA), ObsEva SA (OBSV)
Source: https://incomestatements.info
Category: Stock Reports